Key result
Fingolimod cuts fibrosis ~48% in mice with chronic Chagas cardiomyopathy but fails to restore cardiac function.
Why the study?
Chronic Chagas cardiomyopathy has limited therapeutic options once established, leading investigators to evaluate the functional S1P receptor modulator Fingolimod given the role of S1P signaling in immune regulation and cardiovascular homeostasis.
Does Fingolimod improve cardiac inflammation, fibrosis, and functional outcomes in a murine model of established chronic Chagas cardiomyopathy?
Does Fingolimod improve cardiac inflammation, fibrosis, and functional outcomes in a murine model of established chronic Chagas cardiomyopathy?
Fingolimod attenuates pathological myocardial inflammation and fibrosis in chronic Chagas cardiomyopathy but does not restore cardiac electrical or functional capacity, suggesting it may be useful only as an adjunct to antiparasitic therapy.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications in Chagas cardiomyopathy; leaves open translation of fibrosis reduction to human disease or functional benefit.
Chronic Chagas cardiomyopathy (CCC), caused by Trypanosoma cruzi infection, is characterized by persistent inflammation, progressive fibrosis, and cardiac dysfunction, with limited therapeutic options once cardiomyopathy is established. Given the central role of sphingosine-1-phosphate (S1P) signaling in immune regulation and cardiovascular homeostasis, we investigated the therapeutic effects of Fingolimod, a functional S1P receptor modulator, in a murine model of established CCC. Chronically infected C57BL/6 mice were orally treated with Fingolimod (0.3 mg·kg⁻ 1 ), and cardiac inflammation, fibrosis, gene expression, cytokine production, parasite burden, and functional outcomes were evaluated. Fingolimod significantly reduced myocardial leukocyte infiltration, collagen deposition, galectin-3 expression, cardiac expression of inflammatory and profibrotic genes, and circulating IFN-γ and TNF-α levels, supporting attenuation of Th1-driven inflammation and inflammatory sphingolipid signaling. In vitro, Fingolimod attenuated macrophage activation by reducing cytokine and nitric oxide production but showed limited activity against bloodstream T. cruzi trypomastigotes. Cardiac connexin 43 (Cx43) distribution was also qualitatively assessed, revealing persistent gap junction disorganization in infected mice with no apparent normalization following Fingolimod treatment. However, these anti-inflammatory and antifibrotic effects were not accompanied by significant reductions in myocardial parasite burden, recovery of exercise capacity, or reversal of established electrocardiographic abnormalities. Together, these findings indicate that pharmacological modulation of S1P signaling attenuates pathological myocardial inflammation and remodeling but is insufficient to control parasite burden or restore cardiac function in established experimental CCC. These results support the potential of Fingolimod as an immunomodulatory strategy that could be explored as an adjunct to antiparasitic therapy, particularly to target persistent inflammatory and fibrotic processes that may continue despite parasite-directed treatment. Further studies evaluating combined antiparasitic and S1P-targeted therapies, as well as cardiovascular safety and optimal treatment regimens, are warranted.
No takes yet. Share an insight, caveat, or question.
Vasconcelos et al. (2026) studied Chronic Chagas cardiomyopathy (n=30). Fingolimod vs. Vehicle (saline containing DMSO) was evaluated on Myocardial fibrosis (collagen deposition) (48.34% reduction, p=0.0011). Fingolimod treatment significantly reduced myocardial fibrosis by 48.34% and inflammatory infiltrates by 22.17% in mice with established chronic Chagas cardiomyopathy, but failed to restore cardiac function.
Synapse has enriched 10 related papers. Consider them for comparative context: